Search

Displaying results 2901 - 2910 of 10000 in total
  1. Target

    cGMP-specific 3',5'-cyclic phosphodiesterase

    go.drugbank.com/bio_entities/BE0000182
    TargetEnzymeHumans

    This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:15489334, PubMed:9714779). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334)

    Polypeptides: cGMP-specific 3',5'-cyclic phosphodiesteraseFunction: 3',5'-cyclic-AMP phosphodiesterase activity
  2. Target

    3',5'-cyclic-AMP phosphodiesterase 4B

    go.drugbank.com/bio_entities/BE0000487
    TargetHumans

    Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes (PubMed:15260978). May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to...

    Polypeptides: 3',5'-cyclic-AMP phosphodiesterase 4BFunction: 3',5'-cyclic-AMP phosphodiesterase activity
  3. Target

    Delta-1-pyrroline-5-carboxylate synthase

    go.drugbank.com/bio_entities/BE0000823
    TargetHumans

    Bifunctional enzyme that converts glutamate to glutamate 5-semialdehyde, an intermediate in the biosynthesis of proline, ornithine and arginine

    Polypeptides: Delta-1-pyrroline-5-carboxylate synthase
  4. Target

    5-aminolevulinate synthase, erythroid-specific, mitochondrial

    go.drugbank.com/bio_entities/BE0000898
    TargetHumans

    Catalyzes the pyridoxal 5'-phosphate (PLP)-dependent condensation of succinyl-CoA and glycine to form aminolevulinic acid (ALA), with CoA and CO2 as by-products (PubMed:14643893, PubMed:21252495, PubMed

    Polypeptides: 5-aminolevulinate synthase, erythroid-specific, mitochondrialSynonyms: 5-aminolevulinic acid synthase 2
  5. Target

    3',5'-cyclic-AMP phosphodiesterase 4A

    go.drugbank.com/bio_entities/BE0001133
    TargetHumans

    Hydrolyzes the second messenger 3',5'-cyclic AMP (cAMP), which is a key regulator of many important physiological processes

    Polypeptides: 3',5'-cyclic-AMP phosphodiesterase 4AFunction: 3',5'-cyclic-AMP phosphodiesterase activity
  6. Target

    3',5'-cyclic-AMP phosphodiesterase 4C

    go.drugbank.com/bio_entities/BE0002353
    TargetHumans

    Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes

    Polypeptides: 3',5'-cyclic-AMP phosphodiesterase 4CFunction: 3',5'-cyclic-AMP phosphodiesterase activity
  7. Target

    Baculoviral IAP repeat-containing protein 5

    go.drugbank.com/bio_entities/BE0003408
    TargetHumans

    Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis (PubMed:20627126, PubMed:21364656, PubMed:25778398, PubMed:28218735, PubMed:9859993). Component of a chromosome passage protein complex (CP...

    Polypeptides: Baculoviral IAP repeat-containing protein 5
  8. Target

    Serine/threonine-protein kinase PAK 5

    go.drugbank.com/bio_entities/BE0009510
    TargetHumans

    Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell migration, proliferation or cell survival. Activation by various effectors including growth factor rec...

    Polypeptides: Serine/threonine-protein kinase PAK 5Synonyms: PAK-5, p21-activated kinase 5
  9. Drug

    Fingolimod

    go.drugbank.com/drugs/DB08868
    ApprovedInvestigational

    Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. … It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.

    Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesProducts: FINGOLIMOD EG, LEBRINA® 0.5 MG
  10. Drug

    Desmopressin

    go.drugbank.com/drugs/DB00035
    ApprovedInvestigational

    It is considered a first-line therapy for central diabetes insipidus but is ineffective in patients with nephrogenic diabetes insipidus, where the kidneys are non-responsive to the hormone [A275458, L56105 … On January 15, 2026, the FDA approved a new low-dose sublingual film formulation specifically for the treatment of nocturia in patients at high risk for fluid overload, utilizing a specialized delivery

    Synonyms: 1 deamino 8 D argininevasopressin, 1-(3-mercaptopropionic acid)-8-D-arginine-vasopressinProducts: DESMOPRESIN®0.2 MG, DESMOVITAL %0,1 MG/ML BURUN SPREYI, 6 ML